Patients with relapsed or refractory (r/r) follicular lymphoma live longer when they are treated with the novel anti-CD19 chimeric antigen receptor T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) than when they are treated with other current therapies, suggests a new analysis.
The new results for overall survival with axi-cel come from the ZUMA-5 study. Those results were compared with data from an international cohort of similar patients who received current therapies.
"The substantial overall survival benefit seen in this study suggests that axi-cel addresses an important unmet medical need or r/r follicular lymphoma patients," commented first author John G. Gribben, DSc. "These data support that axi-cel represents a significant improvement in treatment options for patients with r/r follicular lymphoma."
Gribben is director of the Experimental Cancer Medicine Center and director of stem cell transplantation at Saint Bartholomew's Hospital, Queen Mary's School of Medicine, University of London, United Kingdom.
He is also the current president of the European Hematology Association. He was presenting the new findings in a late-breaker abstracts session at the virtual European Hematology Association (EHA) 2021 Annual Meeting.
Commenting on the study, Kirsten Gronbaek, MD, a professor of hematology at Rigshospitalet, in Copenhagen, Denmark, and co-moderator of the EHA session, said the study's findings are encouraging.
"I think these are very impressive results that give new hope for patients with relapsed/refractory follicular lymphoma,"she told Medscape Medical News.
Axi-cel was recently approved by the US Food and Drug Administration for the treatment of adult patients with r/r follicular lymphoma after receiving two or more lines of systemic therapy. This approval in March 2021 was based on data from this ZUMA-5 trial.
The product was already on the market, having first been approved in 2017 for the treatment of large B-cell lymphoma in patients who experience disease progression after receiving two previous lines of therapy. That approval was based on the results from the ZUMA-1 pivotal trial.
ZUMA-5 was a pivotal trial that showed for the first time that CAR T-cell therapy yielded a high response rate (94%) in r/r indolent non-Hodgkin lymphoma and a 12-month overall survival rate of 92.9%.
At the EHA meeting, Gribben and colleagues reported updated results from ZUMA-5.
They compared these results to results from a matched sample of patients with r/r follicular lymphoma in the international SCHOLAR-5 external control cohort who met the ZUMA-5 eligibility requirements and were treated in the real-world setting with currently available therapies.
In the propensity-matched groups, there were 86 patients with r/r follicular lymphoma in the ZUMA-5 cohort. (median follow-up, 23.3 months) and 85 patients in the SCHOLAR cohort (median follow-up, of 26.2 months).
The groups were matched and balanced at baseline with regard to age, sex, having received at least two prior lines of therapy, having undergone prior stem cell therapy, and other factors.
Treatments received in the SCHOLAR cohort were wide ranging and included stem cell transplant, anti-CD20-chemotherapy combinations, and other chemotherapy. Patients were also included from Gilead's Delta trial of idelalisib (n = 25).
"What was clear to us is the treatment of relapsed/refractory follicular lymphoma is extremely heterogeneous in clinical practice, and this highlights the lack of uniform treatment options for these patients," Gribben said.
He added that "experimental treatment options were commonly used in late-line follicular lymphoma treatment."
Among the patients in both studies who were treated with at least two prior lines of therapy, the overall response rate was substantially higher in the ZUMA-5 trial, at 94.2%, vs 49.9% in the SCHOLAR cohort, for an odds ratio (OR) of 16.2 (P < .0001).
The complete response rates among those patients were 79.1% vs 29.9% (OR, 8.86; P < .0001).
Although the median rate of progression-free survival was not reached in the ZUMA-5 trial, in the SCHOLAR cohort, the rate was 12.7 months (hazard ratio [HR], 0.30; P < .001).
Importantly, the median overall survival was not reached in ZUMA-5 and was 59.8 months with the SCHOLAR cohort (HR, 0.42; P = .0125).
The median time to next treatment was significantly longer in the ZUMA-5 trial (not reached) in comparison with SCHOLAR-5 (14.43; HR, 0.42; P < .001).
Similar responses were observed in all outcomes among patients who had received three or more prior lines of therapy.
"After applying a propensity score method, axi-cel demonstrated a substantial improvement in all clinical endpoints in the ZUMA-5 clinical trial when compared to SCHOLAR-5, and these findings were maintained across the prespecified sensitivity analyses," Gribben said.
"The overall response rate, complete remission, progression-free survival, and time-to-next-treatment comparisons showed statistically significant improvements, highlighting the deep and durable treatment effect of axi-cel in this patient population," he added.
In further comments, Gronbaek said that the study is notable for its use of the international cohort instead of a traditional randomized trial design.
"This is a very interesting approach, and as we gather more and more data, for instance, in the HARMONY Alliance projects...this may offer even better opportunities to identify matching controls in the future. It will also be interesting when patients can be matched according to molecular features in the future," Gronbaek said.
The study was supported by Kite, a Gilead company. Gribben reported relationships with Kite, Janssen, Bristol-Myers Squibb, AstraZeneca, AbbVie, Morphosys, Novartis, Takeda. and TG Therapeutics. Gronbaek has disclosed no relevant financial relationships..
European Hematology Association (EHA) 2021 Annual Meeting: Abstract S130. Presented June 11, 2021.
For more news, follow Medscape on Facebook, Twitter, Instagram, and YouTube.
Read the rest here:
'Impressive Results' With CAR T-cell in R/R Follicular Lymphoma - Medscape
- SUM Hospital conducts Odishas first stem cell transplantation - The Times of India - April 24th, 2024
- Cancer treatment: What is stem cell therapy, and how does it work? - Moneycontrol - April 24th, 2024
- The murky, unregulated world of anti-ageing stem cell therapy - The Telegraph - April 24th, 2024
- Drug Prototype Promising in Treatment of Pulmonary Disease - Medscape - April 20th, 2024
- Man Paralyzed In Surfing Accident Regains Ability to Walk After Stem Cell Treatment - The Inertia - April 20th, 2024
- Medical breakthrough: 8-year-old boy first in New York to receive FDA-approved gene therapy for rare inherited blood disorder - WABC-TV - April 20th, 2024
- Stem Cell Treatment Helped A Man Who Was Paralyzed From The Neck Down To Stand On His Own - Bored Panda - April 20th, 2024
- UM, CUHK jointly hold symposium on stem cells and regenerative medicine - gcs.gov.mo - April 20th, 2024
- Paralysed patient now able to walk as stem cell therapy shows promising results - WION - April 15th, 2024
- Andrew Steele Sees Aging as the Root of Disease - Worth - Worth Magazine - April 15th, 2024
- The astonishing effect of stem cell implants - as groundbreaking treatment 'transforms' life for those with brain damage ... - Daily Mail - April 15th, 2024
- Consumer Alert on Regenerative Medicine Products Including Stem Cells - FDA.gov - April 13th, 2024
- This Startup Wants To Be OpenAI Of Stem Cell Therapy, Targets $250B Market - Forbes - April 13th, 2024
- Brain-cell transplants are the newest experimental epilepsy treatment - MIT Technology Review - April 3rd, 2024
- Global Regenerative Medicine Market to Touch Valuation of USD 472.95 Billion by 2032, at 25.86% CAGR: Astute ... - Yahoo Finance - April 1st, 2024
- Explosive Growth Projected for Stem Cell Market, Expected to Surpass $37 Billion by 2030 As Revealed In New... - WhaTech - April 1st, 2024
- Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma - Targeted Oncology - April 1st, 2024
- New tool provides researchers with improved understanding of stem cell aging in the brain - Medical Xpress - March 30th, 2024
- The ISSCR announces 2024 election results - EurekAlert - March 28th, 2024
- Exosomes and Stem Cells Are the Future of Anti-Aging - NewBeauty Magazine - March 28th, 2024
- Charles River Extends Gene Therapy Alliance with NUS Medicine - Contract Pharma - March 22nd, 2024
- Exciting opportunities in stem cell technology and regenerative biology in Indian healthcare industry - Express Healthcare - March 22nd, 2024
- Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine - Yahoo Finance - March 22nd, 2024
- Opinion: The revolutionary sickle cell therapies - MSN - March 22nd, 2024
- 10 Years of Kansas Regenerative Medicine Center - KSAL - March 22nd, 2024
- BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership - Diagnostic and Interventional Cardiology - March 17th, 2024
- Cynata Therapeutics' breakthrough in regenerative medicine - Finance News Network - March 17th, 2024
- New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia - GlobeNewswire - March 17th, 2024
- Novel 3D stem cell therapy to treat critical limb ischaemia - Drug Target Review - March 15th, 2024
- Breaking Boundaries: Pharmicell's Bold Vision for Healthcare Transformation and Monumental Growth - The Worldfolio - March 15th, 2024
- CuSTOM Organoid Research Evolving From Tool to Treatment - Research Horizons - Research Horizons - March 15th, 2024
- BioCardia and StemCardia Announce Partnership to Deliver Cell-Gene Therapy for Remuscularization of Heart - Cath Lab Digest - March 15th, 2024
- Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine ... - Business Wire - March 13th, 2024
- Iron restriction keeps blood stem cells young, researchers find - Phys.org - March 13th, 2024
- Vitamin A could have a key role in both stem cell biology and wound healing: Study - Medical Dialogues - March 9th, 2024
- Trends in Stem Cell Transplantation Refusal for Myeloma Treatment - Targeted Oncology - March 7th, 2024
- Stem Cell Therapy Market (CAGR) of 31.1%, Future of Market Size Emerging Technologies and their Impact on ... - Taiwan News - March 7th, 2024
- This Swedish startup wants to reduce the cost, and controversy, around stem cell production - TechCrunch - March 6th, 2024
- Advancing stem cell therapy: The regulatory process to get to clinical trials - The Economic Times - March 6th, 2024
- Transitioning from traditional surgical methods to the innovative use of stem cells - pharmaphorum - March 6th, 2024
- 'Mini organs' are grown from human stem cells taken during the late stages of pregnancy for the first time - m - Daily Mail - March 6th, 2024
- Stem cell transplant cures man of HIV and leukemia, one of five to achieve full remission - Fox 28 - March 3rd, 2024
- Stem Cell Therapy Market to Boost USD 137.5 Billion by 2034 and Projected to grow at 32.10% CAGR with increasing ... - Yahoo Finance - March 1st, 2024
- Studies expand use of stem cell therapies - WPLG Local 10 - March 1st, 2024
- Innovative therapy targets and destroys leukemia stem cells - News-Medical.Net - February 27th, 2024
- Unlocking the Potential of Stem Cells: The Medical Revolution of the Century - EIN News - February 27th, 2024
- Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine ... - Yahoo Finance - February 27th, 2024
- Say Her Name - Henrietta Lacks, The Real Mother Of Stem - Her Campus - February 27th, 2024
- California Man Free of HIV And Cancer in Astonishing Medical Recovery - ScienceAlert - February 25th, 2024
- $93 million for research into improved health for children, young people and the aged, medical devices, mental health ... - Department of Health - February 25th, 2024
- Stem Cells in Regenerative Medicine - PMC - National Center for ... - February 24th, 2024
- The Promise and Reality of Stem Cell Therapy: What You Need to Know - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy: A Beacon of Hope for Patients with Untreatable Conditions - Corporate Wellness Magazine - February 22nd, 2024
- Leading Experts in Stem Cell Therapy: A Global Overview - Corporate Wellness Magazine - February 22nd, 2024
- Can Stem Cells Help Reverse the Effects of Aging? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy for Cancer: Hope on the Horizon? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cells and Autism: A Closer Look at Innovative Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Regrowth and Restoration: The Science Behind Stem Cell Therapy for Hair - Corporate Wellness Magazine - February 22nd, 2024
- Brain Recovery: The Role of Stem Cells in Stroke and Cerebral Palsy Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Turning Back the Clock: The Science of Stem Cells in Anti-Aging - Corporate Wellness Magazine - February 22nd, 2024
- Insights into cellular therapies for cancer treatment - Drug Target Review - February 22nd, 2024
- The Role of Stem Cells in Rheumatoid Arthritis Recovery - Corporate Wellness Magazine - February 22nd, 2024
- Dr Ernesto Romeros vision transforms immunotherapy regenerative medicine into a global leader in stem cell treatment - Khaleej Times - February 22nd, 2024
- World-Renowned Doctors Leading the Way in Stem Cell Research and Treatment - Medical Tourism Magazine - February 20th, 2024
- Choosing the Best: A Guide to America's Premier Stem Cell Therapy Providers - Medical Tourism Magazine - February 20th, 2024
- Navigating Through the Possibilities of Stem Cell Treatment for Eye Disorders - Medical Tourism Magazine - February 20th, 2024
- Global Leaders in Stem Cell Therapy: Where Excellence Meets Innovation - Medical Tourism Magazine - February 20th, 2024
- Excellence in Stem Cell Treatment: How the US is Pioneering Global Healthcare Solutions - Medical Tourism Magazine - February 20th, 2024
- Clarifying Memory Loss Treatments: The Role of Stem Cells - Medical Tourism Magazine - February 20th, 2024
- Battling Inflammation: Stem Cell Therapy for Rheumatoid Arthritis - Medical Tourism Magazine - February 20th, 2024
- Digestive Health and Stem Cells: Treating Ulcerative Colitis and Crohn's Disease - Medical Tourism Magazine - February 20th, 2024
- Top Stem Cell Clinics in the USA: Pioneering Treatments for Chronic Conditions - Medical Tourism Magazine - February 20th, 2024
- Stem Cells and Autism: Understanding the Potential for Innovative Treatments - Medical Tourism Magazine - February 20th, 2024
- Stopping the awakening of sleeping Acute Myeloid Leukaemia stem cells to prevent disease relapse - University of Birmingham - February 20th, 2024
- City of Hope Achieves Ground Breaking Treatment for Blood Cancer and HIV - Medriva - February 18th, 2024
- Regenerative Medicine Market Size to Worth USD 95 Billion by 2032 - InvestorsObserver - February 18th, 2024
- North America Organoids Market Projected to Reach US$ 5.35 Billion by 2030, Riding on a CAGR of 21.5% - GlobeNewswire - February 18th, 2024
- Chinese team tests lung treatment that may be first to reverse COPD damage - South China Morning Post - February 15th, 2024
- Why leukemic stem cells not harmed by chemotherapy begin to grow and produce AML cells after treatment - Medical Xpress - February 15th, 2024
- Regenerative Medicine Market is Expected to Reach $49.0 Billion | MarketsandMarkets - Yahoo Finance - February 15th, 2024
Recent Comments